Gsa Capital Partners LLP Oncocyte Corp Transaction History

Gsa Capital Partners LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	BUY	$0.86 - $1.53 $1,921 - $3,418	2,234 Added 1.41%	160,238 $144,000
Q1 2022 May 11, 2022	SELL	$1.15 - $2.25 $108,438 - $212,161	-94,294 Reduced 37.37%	158,004 $235,000
Q4 2021 Feb 14, 2022	BUY	$2.04 - $3.59 $514,687 - $905,749	252,298 New	252,298 $547,000
Q3 2021 Nov 12, 2021	SELL	$3.53 - $5.89 $132,872 - $221,705	-37,641 Closed	0 $0
Q2 2021 Aug 05, 2021	SELL	$3.77 - $6.0 $26,333 - $41,910	-6,985 Reduced 15.65%	37,641 $216,000
Q1 2021 May 10, 2021	SELL	$2.39 - $6.5 $299,992 - $815,880	-125,520 Reduced 73.77%	44,626 $232,000
Q4 2020 Feb 03, 2021	SELL	$1.38 - $2.63 $42,643 - $81,269	-30,901 Reduced 15.37%	170,146 $407,000
Q3 2020 Nov 06, 2020	BUY	$1.2 - $1.89 $241,256 - $379,978	201,047 New	201,047 $279,000

411K

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $260M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.